Latest Neuroprotection Stories
JACKSONVILLE, Fla., Nov. 17 /PRNewswire/ -- Sinapis Pharma, Inc. has successfully completed a Series "A" Preferred stock offering that has raised $510,000 for its ongoing drug development program.
CLARKSVILLE, Md., Nov.
Scientists at the University of California, San Diego School of Medicine report that regeneration of central nervous system axons can be achieved in rats even when treatment delayed is more than a year after the original spinal cord injury.
The inflammatory response following a spinal cord injury appears to be set up to cause extra tissue damage instead of promoting healing, new research suggests.
Glutamate is to the brain like coffee is to our bodies. A cup of Joe in the morning can wake us, but overloading on caffeine causes the stimulant to work against us.
The antibiotic minocycline may revolutionize the treatment of strokes. A new study, published in the open access journal BMC Neuroscience, describes the safety and therapeutic efficacy of the drug in animal models.
NEW YORK, Sept. 23 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation has committed up to $5 million for research to successfully translate neurotrophic factor advances from pre-clinical and early-phase clinical work into a practical, patient-relevant treatment for Parkinson's disease.
BOULDER, Colo., Sept. 17 /PRNewswire/ -- Bolder BioTechnology, Inc.
A new study finds substantial improvement in a mouse model of a rare, hereditary neurodegenerative disease after transplantation of normal human neural stem cells.
Parkinsonâ€™s disease is caused by the degeneration of neurons in the midbrain. The mechanisms leading to the loss of these neurons, however, are largely unknown.